Neuromyelitis Optica Drug Industry Research Report 2024

April 2024 | 118 pages | ID: NC440262524FEN
APO Research

Abstracts

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

According to APO Research, The global Neuromyelitis Optica Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

• Pfizer
• Fresenius
• Teva
• Sandoz
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL
• Grifols
• Octapharma
• CBOP

Neuromyelitis Optica Drug segment by Type

• Glucocorticoids
• Immunotherapies
• Others

Neuromyelitis Optica Drug Segment by Application

• Acute Attack
• Remission Prophylactic Treatment

Neuromyelitis Optica Drug Segment by Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
  1.5.1 Secondary Sources
  1.5.2 Primary Sources

2 MARKET OVERVIEW

2.1 Product Definition
2.2 Neuromyelitis Optica Drug by Type
  2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
  2.2.2 Glucocorticoids
  2.2.3 Immunotherapies
  2.2.4 Others
2.3 Neuromyelitis Optica Drug by Application
  2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
  2.3.2 Acute Attack
  2.3.3 Remission Prophylactic Treatment
2.4 Assumptions and Limitations

3 NEUROMYELITIS OPTICA DRUG BREAKDOWN DATA BY TYPE

3.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2019-2024)
3.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030)

4 NEUROMYELITIS OPTICA DRUG BREAKDOWN DATA BY APPLICATION

4.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2019-2024)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

5.1 Global Neuromyelitis Optica Drug Market Perspective (2019-2030)
5.2 Global Neuromyelitis Optica Drug Growth Trends by Region
  5.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
  5.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2019-2024)
  5.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030)
5.3 Neuromyelitis Optica Drug Market Dynamics
  5.3.1 Neuromyelitis Optica Drug Industry Trends
  5.3.2 Neuromyelitis Optica Drug Market Drivers
  5.3.3 Neuromyelitis Optica Drug Market Challenges
  5.3.4 Neuromyelitis Optica Drug Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Neuromyelitis Optica Drug Players by Revenue
  6.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2019-2024)
  6.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2019-2024)
6.2 Global Neuromyelitis Optica Drug Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served
6.4 Global Neuromyelitis Optica Drug Players, Product Type & Application
6.5 Global Neuromyelitis Optica Drug Players, Date of Enter into This Industry
6.6 Global Neuromyelitis Optica Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Neuromyelitis Optica Drug Market Size (2019-2030)
7.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
7.4 North America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
7.5 United States
7.6 Canada

8 EUROPE

8.1 Europe Neuromyelitis Optica Drug Market Size (2019-2030)
8.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024)
8.4 Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2019-2030)
9.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Country (2019-2024)
9.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia

10 LATIN AMERICA

10.1 Latin America Neuromyelitis Optica Drug Market Size (2019-2030)
10.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024)
10.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2019-2030)
11.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2019-2024)
11.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE

12 PLAYERS PROFILED

12.1 Pfizer
  12.1.1 Pfizer Company Information
  12.1.2 Pfizer Business Overview
  12.1.3 Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio
  12.1.5 Pfizer Recent Developments
12.2 Fresenius
  12.2.1 Fresenius Company Information
  12.2.2 Fresenius Business Overview
  12.2.3 Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio
  12.2.5 Fresenius Recent Developments
12.3 Teva
  12.3.1 Teva Company Information
  12.3.2 Teva Business Overview
  12.3.3 Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.3.4 Teva Neuromyelitis Optica Drug Product Portfolio
  12.3.5 Teva Recent Developments
12.4 Sandoz
  12.4.1 Sandoz Company Information
  12.4.2 Sandoz Business Overview
  12.4.3 Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio
  12.4.5 Sandoz Recent Developments
12.5 Intas
  12.5.1 Intas Company Information
  12.5.2 Intas Business Overview
  12.5.3 Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.5.4 Intas Neuromyelitis Optica Drug Product Portfolio
  12.5.5 Intas Recent Developments
12.6 Gyjtrs
  12.6.1 Gyjtrs Company Information
  12.6.2 Gyjtrs Business Overview
  12.6.3 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio
  12.6.5 Gyjtrs Recent Developments
12.7 NANG KUANG
  12.7.1 NANG KUANG Company Information
  12.7.2 NANG KUANG Business Overview
  12.7.3 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio
  12.7.5 NANG KUANG Recent Developments
12.8 Tianjin Kingyork
  12.8.1 Tianjin Kingyork Company Information
  12.8.2 Tianjin Kingyork Business Overview
  12.8.3 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio
  12.8.5 Tianjin Kingyork Recent Developments
12.9 Baxter
  12.9.1 Baxter Company Information
  12.9.2 Baxter Business Overview
  12.9.3 Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio
  12.9.5 Baxter Recent Developments
12.10 CSL
  12.10.1 CSL Company Information
  12.10.2 CSL Business Overview
  12.10.3 CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.10.4 CSL Neuromyelitis Optica Drug Product Portfolio
  12.10.5 CSL Recent Developments
12.11 Grifols
  12.11.1 Grifols Company Information
  12.11.2 Grifols Business Overview
  12.11.3 Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio
  12.11.5 Grifols Recent Developments
12.12 Octapharma
  12.12.1 Octapharma Company Information
  12.12.2 Octapharma Business Overview
  12.12.3 Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio
  12.12.5 Octapharma Recent Developments
12.13 CBOP
  12.13.1 CBOP Company Information
  12.13.2 CBOP Business Overview
  12.13.3 CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024)
  12.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio
  12.13.5 CBOP Recent Developments

13 REPORT CONCLUSION

14 DISCLAIMER